Medically reviewed by Onikepe Adegbola, MD, PhD
A research paper was published in the Brazilian Journal of Biology, titled “Using Bifidobacterium and Propionibacterium Strains in Probiotic Consortia to Normalize the Gastrointestinal Tract.“
Based on expert opinions in the study, the microorganisms Bifidobacterium and Propionibacterium genera qualities can be preserved and encapsulated. This research backs up expert suggestions with clinical evidence, proving that the experts were correct.
The gut microflora is responsible for regulating the body’s activities and maintaining its health. Diabetes, obesity, inflammation, atherosclerosis, and other chronic diseases are due to dysbiosis.
In the 2024 recommendations, experts recommended probiotics for living microorganisms that benefit the microflora and improve the health of the host organism helping prevent these diseases. Lactic acid bacteria from the Bifidobacterium and Propionibacterium genera are the frequent probiotics recommended.
Bifidobacterium adolescentis-1909, Bifidobacterium longum infantis-1912, Propionibacterium jensenii B-6085, Propionibacterium freudenreichii -11921, Propionibacterium thoenii -6082, and Propionibacterium acidipropionici-5723 were examined for their probiotic characteristics in the study.
This study was conducted in the Laboratory for Bio testing Natural Nutraceuticals at Kemerovo State University (Russia). The study used collection strains of the lactic acid bacteria Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichiiВ-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Lactic acid cultures were tested for antibacterial activity against the test cultures Salmonella enterica ATCC 14028, Staphylococcus aureusATCC 25923, Pseudomonas aeruginosa B6643, Proteus Vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Additionally, the antibiotic resistance of lactic acid cultures was tested using the disk diffusion method.
Bifidobacterium adolescentis-1909, Propionibacterium jensenii B-6085, and Propionibacterium thoenii 6082 showed moderate antibacterial activities against all test cultures. According to research, some Propionibacterium and Bifidobacterium strains, or their consortia, could be employed as probiotic cultures in dietary supplements or functional foods to prevent various chronic diseases like IBS.
Why is this study important for patients with IBS Symptoms
Although IBS is bothersome and inconvenient, it does not increase the chance of developing other health problems. However, the success of the treatment depends on what grade of IBS it is and how it is addressed.
Bifidobacterium bacteria are particularly significant compared with other gut microbiota in probiotic cultures. Probiotics have a favorable effect in four ways. First, they produce antimicrobial compounds. Second, they are hostile to pathogenic and opportunistic strains. They also adhere to epithelial cells (cells of intestinal walls), posing a competitive threat to disease-causing bacteria. Finally, they inhibit the production of metabolites by pathogenic bacteria and cancer cells.
What is the Key Takeaway from this Study
Large doses of probiotics that contain these bacteria in dietary supplements or functional fermented milk products can stimulate their proliferation in the large intestine.
The development of functional foods containing probiotics, particularly Bifidobacterium strains, is driven by the increased demand for health-beneficial foods. However, Propionibacterium ‘dairy’ strains have recently gained popularity.
As a result, probiotic consortia of these species can be established to normalize the gastrointestinal microbiota’s function. To preserve their quality, these microorganisms can be encapsulated (immobilized). All the strains can be employed to form various dietary supplements or functional product consortia.
References:
Dyshlyuk, L. S., Milentyeva, I. S., Asyakina, L. K., Ostroumov, L. A., Osintsev, A. M., & Pozdnyakova, A. V. (2024). Using Bifidobacterium and Propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract. Brazilian Journal of Biology, 84. https://doi.org/10.1590/1519-6984.256945
Comments 1